N-methyl-D-aspartate receptors participate in schizophrenia and cognitive disorders such as dementia and Parkinson’s disease, in which GluN1, GluN2A, and GluN2B expression is decreased (Cull-Candy et al., 2001; Zhang et al., 2015). This evidence concerns the gene GRIN1 and cognitive disorder.